论文部分内容阅读
目的:观察前列腺素E1(PGE1)治疗冠心病心力衰竭的临床效果。方法:病人随机分为PGE1治疗组(40例)和对照组(40例)。治疗组用PGE110ug加入5%葡萄糖溶液250ml静滴,每日1次,10d为一疗程。对照组除不用PGE1外,其他治疗与PGE1治疗组相同。治疗后测定血BNP、无创血流动力学监测心输出量(CO)、心脏指数(CI)、肺动脉楔压(PCWP)以及测定血小板数值。结果:PGE1治疗组血BNP水平较对照组明显下降(P<0.05);无创性心功能监测CI、CO较对照组明显增加,PCWP较对照组下降(P<0.05);血小板较对照组明显减少(P<0.05)。结论:PGE1能改善冠心病心衰患者心功能,其疗效肯定。
Objective: To observe the clinical effect of Prostaglandin E1 (PGE1) in the treatment of heart failure with coronary heart disease. Methods: The patients were randomly divided into PGE1 treatment group (40 cases) and control group (40 cases). Treatment group with PGE1ug add 5% glucose solution 250ml intravenous infusion, once daily, 10d for a course of treatment. The control group except PGE1, other treatment and PGE1 treatment group the same. Blood BNP, noninvasive hemodynamic monitoring of cardiac output (CO), cardiac index (CI), pulmonary artery wedge pressure (PCWP) and platelet count were measured after treatment. Results: Compared with the control group, the levels of plasma BNP in PGE1 treatment group decreased significantly (P <0.05); the CI and CO in noninvasive cardiac function monitoring increased significantly compared with the control group, while the PCWP decreased compared with the control group (P <0.05); the platelet count decreased significantly (P <0.05). Conclusion: PGE1 can improve cardiac function in patients with heart failure of coronary heart disease, and the curative effect is definite.